Sökning: WFRF:(Asklid Anna)
> (2016) >
Real-world results ...
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
-
- Winqvist, Maria (författare)
- Karolinska Institutet
-
- Asklid, Anna (författare)
- Karolinska Institutet
-
- Andersson, P. O. (författare)
- South Älvsborg Hospital, Sweden
-
visa fler...
-
- Karlsson, Karin (författare)
- Skåne University Hospital, Sweden
-
- Karlsson, Claes (författare)
- Karolinska Institutet
-
- Lauri, Birgitta (författare)
- Sunderby Hospital, Sweden
-
- Lundin, Jeanette (författare)
- Karolinska Institutet
-
- Mattsson, Mattias (författare)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
- Norin, Stefan (författare)
- Karolinska Institutet
-
- Sandstedt, Anna (författare)
- Linköpings universitet,Institutionen för samhälls- och välfärdsstudier,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Hansson, Lotta (författare)
- Karolinska Institutet
-
- Osterborg, Anders (författare)
- Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2016-05-19
- 2016
- Engelska.
-
Ingår i: Haematologica. - : FERRATA STORTI FOUNDATION. - 0390-6078 .- 1592-8721. ; 101:12, s. 1573-1580
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://doi.org/10.3...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Ibrutinib, a Brutons tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine healthcare are commonly observed in oncology. Herein we report real-world results for 95 poor prognosis Swedish patients treated with ibrutinib in a compassionate use program. Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included in the study between May 2014 and May 2015. The median age was 69 years. 63% had del(17p)/TP53 mutation, 65% had Rai stage III/IV, 28% had lymphadenopathy amp;gt;= 10cm. Patients received ibrutinib 420 mg once daily until progression. At a median follow-up of 10.2 months, the overall response rate was 84% (consistent among subgroups) and 77% remained progression-free. Progression-free survival and overall survival were significantly shorter in patients with del(17p)/TP53 mutation (P=0.017 and P=0.027, log-rank test); no other factor was significant in Cox proportional regression hazards model. Ibrutinib was well tolerated. Hematomas occurred in 46% of patients without any major bleeding. Seven patients had Richters transformation. This real-world analysis on consecutive chronic lymphocytic leukemia patients from a well-defined geographical region shows the efficacy and safety of ibrutinib to be similar to that of pivotal trials. Yet, del(17p)/TP53 mutation remains a therapeutic challenge. Since not more than half of our patients would have qualified for the pivotal ibrutinib trial (RESONATE), our study emphasizes that real-world results should be carefully considered in future with regards to new agents and new indications in chronic lymphocytic leukemia.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Winqvist, Maria
-
Asklid, Anna
-
Andersson, P. O.
-
Karlsson, Karin
-
Karlsson, Claes
-
Lauri, Birgitta
-
visa fler...
-
Lundin, Jeanette
-
Mattsson, Mattia ...
-
Norin, Stefan
-
Sandstedt, Anna
-
Hansson, Lotta
-
Osterborg, Ander ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Haematologica
- Av lärosätet
-
Linköpings universitet
-
Uppsala universitet
-
Karolinska Institutet